Advertisement


Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

2024 ASCO Annual Meeting

Advertisement

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
What we are going to look at is to determine the trends in and use of primary hormonal therapy use, and also long-term survival outcomes for hormonal therapy in premenopausal patient with early stage endometrial cancer. The design of this study is retrospective cohort study, and we use national cancer database which registered around 70% of newly diagnosed cases in the US. We have two major parts in this study and the fourth one is looking at the trends in and patterns of use of primary hormonal therapy in the premenopausal patient with early stage endometrial cancer. And the second one is survival outcome for the patient with early stage endometrial cancer. We included patients 18 to 49 years old and clinical stage 1 endometrial cancer and grade one [inaudible 00:01:01] 2 endometrial cancer. Main finding of our study is the utilization rate of primary hormonal therapy rose from 4% to 5% around 2004 to 2010, and it's going up to 12% to 14% in 2020. Younger age, non-white race patients who live in metropolitan area, patient who are treated at academic cancer center, patient who are treated at the facilities located at Northeast area in the US were associated with primary hormonal therapy use. In terms of tumor characteristics, grade 1 and stage 1A were associated with primary hormonal therapy use. For survival outcomes, the propensity score match cohort is well-balanced between the two primary treatment group. Overall, after 10 year follow up, the survival rate was decreased by 4.1% in hormonal therapy group compared with hysterectomy group. Hazard ratio was 1.84. In age subgroup, patient younger than 40 years old, the two primary treatment group of the survival rate was similar at any time point, five year and 10 year point. Surprisingly among age 40 to 49, the survival rate was inferior in hormonal therapy group then hysterectomy group at five year point and 10 year point. Hazard ratio was 4.94. To conclude, given the growing number of patient with early stage endometrial cancer who may desire fertility preservation, we need to consider potentially poorer prognosis when patients and provider select the primary hormonal therapy use. Shared decision making is further needed for this space and also prospective study with large sample sites should be needed for making this evidence more robust.

Related Videos

Leukemia

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).

Multiple Myeloma

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Luciano J. Costa, MD, PhD, of the University of Alabama at Birmingham, discusses recent findings from the CARTITUDE-4 trial showing that, in patients with lenalidomide-refractory functional high-risk multiple myeloma after one prior line of treatment, ciltacabtagene autoleucel improved outcomes vs the standard of care (Abstract 7504).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Lung Cancer

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Advertisement

Advertisement




Advertisement